Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma
Samuel S. Freeman, Moshe Sade-Feldman, Jaegil Kim, Chip Stewart, Anna Gonye, Arvind Ravi, Monica Arniella, Irena Gushterova, Thomas J. LaSalle, Emily M. Blaum, Keren Yizhak, Dennie T. Frederick, Tatyana Sharova, Ignaty Leshchiner, Liudmila Elagina, Oliver Spiro, Dimitri Livitz, Daniel Rosebrock, François Aguet, Jian Carrot‐Zhang, Gavin Ha, Ziao Lin, Jonathan Chen, Michal Barzily-Rokni, Marc R. Hammond, Hans C. Vitzthum von Eckstaedt, Shauna Blackmon, Yunxin J. Jiao, Stacey Gabriel, Donald P. Lawrence, Lyn M. Duncan, Anat Stemmer‐Rachamimov, Jennifer A. Wargo, Keith T. Flaherty, Ryan J. Sullivan, Genevieve M. Boland, Matthew Meyerson, Gad Getz, Nir Hacohen
Abstract
. Overall, RNA or DNA-based models combining immune and tumor measures improve predictions of melanoma CPB outcomes.